

Global Antisense & RNAi Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/G667190A45D6EN.html>

Date: January 2023

Pages: 113

Price: US\$ 3,480.00 (Single User License)

ID: G667190A45D6EN

Abstracts

Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (mRNA) produced by that gene and inactivate it, effectively turning that gene 'off'.

According to our (Global Info Research) latest study, the global Antisense & RNAi Therapeutics market size was valued at USD 986.3 million in 2022 and is forecast to a readjusted size of USD 1303.9 million by 2029 with a CAGR of 4.1% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North America is a key market, with U.S. reflecting a number of RNAi therapeutics currently in developmental pipelines. A number of biotechnology companies have made considerably high investments for RNAi therapeutic development. Big pharmaceutical developers have entered into collaboration agreements or licensing deals with a number of smaller firms in an attempt to capitalize on the expected revenue growth of this market.

This report is a detailed and comprehensive analysis for global Antisense & RNAi Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share

estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Antisense & RNAi Therapeutics market size and forecasts, in consumption value (\$ Million), 2018-2029

Global Antisense & RNAi Therapeutics market size and forecasts by region and country, in consumption value (\$ Million), 2018-2029

Global Antisense & RNAi Therapeutics market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2018-2029

Global Antisense & RNAi Therapeutics market shares of main players, in revenue (\$ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Antisense & RNAi Therapeutics

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Antisense & RNAi Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Glaxo Smith Kline, Sanofi Aventis / Genzyme, Isis Pharmaceuticals/ Ionis Pharmaceuticals, Arbutus Biopharma Ltd. and Silence Therapeutics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Antisense & RNAi Therapeutics market is split by Type and by Application. For the

period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

RNA Interference

SiRNA

MiRNA

Antisense RNA

Market segment by Application

Oncology

Cardiovascular

Renal

Neurodegenerative

Respiratory

Genetic

Infectious Diseases

Market segment by players, this report covers

Glaxo Smith Kline

Sanofi Aventis / Genzyme

Isis Pharmaceuticals/ Ionis Pharmaceuticals

Arbutus Biopharma Ltd.

Silence Therapeutics

Bio-Path Holdings Inc.

Calando Pharmaceuticals

ICo Therapeutics

Quark Pharmaceuticals

Rexhan Pharmaceuticals

Biomarin/Prosensa

Regulus Therapeutics

Rxi Pharmaceuticals

Silenseed

Dicerna Pharmaceuticals

Sirnaomics Inc.

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Antisense & RNAi Therapeutics product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Antisense & RNAi Therapeutics, with revenue, gross margin and global market share of Antisense & RNAi Therapeutics from 2018 to 2023.

Chapter 3, the Antisense & RNAi Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023. and Antisense & RNAi Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Antisense & RNAi Therapeutics.

Chapter 13, to describe Antisense & RNAi Therapeutics research findings and conclusion.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Antisense & RNAi Therapeutics
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Antisense & RNAi Therapeutics by Type
 - 1.3.1 Overview: Global Antisense & RNAi Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
 - 1.3.2 Global Antisense & RNAi Therapeutics Consumption Value Market Share by Type in 2022
 - 1.3.3 RNA Interference
 - 1.3.4 SiRNA
 - 1.3.5 MiRNA
 - 1.3.6 Antisense RNA
- 1.4 Global Antisense & RNAi Therapeutics Market by Application
 - 1.4.1 Overview: Global Antisense & RNAi Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
 - 1.4.2 Oncology
 - 1.4.3 Cardiovascular
 - 1.4.4 Renal
 - 1.4.5 Neurodegenerative
 - 1.4.6 Respiratory
 - 1.4.7 Genetic
 - 1.4.8 Infectious Diseases
- 1.5 Global Antisense & RNAi Therapeutics Market Size & Forecast
- 1.6 Global Antisense & RNAi Therapeutics Market Size and Forecast by Region
 - 1.6.1 Global Antisense & RNAi Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
 - 1.6.2 Global Antisense & RNAi Therapeutics Market Size by Region, (2018-2029)
 - 1.6.3 North America Antisense & RNAi Therapeutics Market Size and Prospect (2018-2029)
 - 1.6.4 Europe Antisense & RNAi Therapeutics Market Size and Prospect (2018-2029)
 - 1.6.5 Asia-Pacific Antisense & RNAi Therapeutics Market Size and Prospect (2018-2029)
 - 1.6.6 South America Antisense & RNAi Therapeutics Market Size and Prospect (2018-2029)
 - 1.6.7 Middle East and Africa Antisense & RNAi Therapeutics Market Size and Prospect (2018-2029)

2 COMPANY PROFILES

2.1 Glaxo Smith Kline

2.1.1 Glaxo Smith Kline Details

2.1.2 Glaxo Smith Kline Major Business

2.1.3 Glaxo Smith Kline Antisense & RNAi Therapeutics Product and Solutions

2.1.4 Glaxo Smith Kline Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.1.5 Glaxo Smith Kline Recent Developments and Future Plans

2.2 Sanofi Aventis / Genzyme

2.2.1 Sanofi Aventis / Genzyme Details

2.2.2 Sanofi Aventis / Genzyme Major Business

2.2.3 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Product and Solutions

2.2.4 Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.2.5 Sanofi Aventis / Genzyme Recent Developments and Future Plans

2.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals

2.3.1 Isis Pharmaceuticals/ Ionis Pharmaceuticals Details

2.3.2 Isis Pharmaceuticals/ Ionis Pharmaceuticals Major Business

2.3.3 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Product and Solutions

2.3.4 Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.3.5 Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Developments and Future Plans

2.4 Arbutus Biopharma Ltd.

2.4.1 Arbutus Biopharma Ltd. Details

2.4.2 Arbutus Biopharma Ltd. Major Business

2.4.3 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Product and Solutions

2.4.4 Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

2.4.5 Arbutus Biopharma Ltd. Recent Developments and Future Plans

2.5 Silence Therapeutics

2.5.1 Silence Therapeutics Details

2.5.2 Silence Therapeutics Major Business

2.5.3 Silence Therapeutics Antisense & RNAi Therapeutics Product and Solutions

2.5.4 Silence Therapeutics Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)

- 2.5.5 Silence Therapeutics Recent Developments and Future Plans
- 2.6 Bio-Path Holdings Inc.
 - 2.6.1 Bio-Path Holdings Inc. Details
 - 2.6.2 Bio-Path Holdings Inc. Major Business
 - 2.6.3 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Product and Solutions
 - 2.6.4 Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.6.5 Bio-Path Holdings Inc. Recent Developments and Future Plans
- 2.7 Calando Pharmaceuticals
 - 2.7.1 Calando Pharmaceuticals Details
 - 2.7.2 Calando Pharmaceuticals Major Business
 - 2.7.3 Calando Pharmaceuticals Antisense & RNAi Therapeutics Product and Solutions
 - 2.7.4 Calando Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.7.5 Calando Pharmaceuticals Recent Developments and Future Plans
- 2.8 ICo Therapeutics
 - 2.8.1 ICo Therapeutics Details
 - 2.8.2 ICo Therapeutics Major Business
 - 2.8.3 ICo Therapeutics Antisense & RNAi Therapeutics Product and Solutions
 - 2.8.4 ICo Therapeutics Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.8.5 ICo Therapeutics Recent Developments and Future Plans
- 2.9 Quark Pharmaceuticals
 - 2.9.1 Quark Pharmaceuticals Details
 - 2.9.2 Quark Pharmaceuticals Major Business
 - 2.9.3 Quark Pharmaceuticals Antisense & RNAi Therapeutics Product and Solutions
 - 2.9.4 Quark Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.9.5 Quark Pharmaceuticals Recent Developments and Future Plans
- 2.10 Rexhan Pharmaceuticals
 - 2.10.1 Rexhan Pharmaceuticals Details
 - 2.10.2 Rexhan Pharmaceuticals Major Business
 - 2.10.3 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Product and Solutions
 - 2.10.4 Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.10.5 Rexhan Pharmaceuticals Recent Developments and Future Plans
- 2.11 Biomarin/Prosensa
 - 2.11.1 Biomarin/Prosensa Details

- 2.11.2 Biomarin/Prosensa Major Business
- 2.11.3 Biomarin/Prosensa Antisense & RNAi Therapeutics Product and Solutions
- 2.11.4 Biomarin/Prosensa Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 2.11.5 Biomarin/Prosensa Recent Developments and Future Plans
- 2.12 Regulus Therapeutics
 - 2.12.1 Regulus Therapeutics Details
 - 2.12.2 Regulus Therapeutics Major Business
 - 2.12.3 Regulus Therapeutics Antisense & RNAi Therapeutics Product and Solutions
 - 2.12.4 Regulus Therapeutics Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.12.5 Regulus Therapeutics Recent Developments and Future Plans
- 2.13 Rxi Pharmaceuticals
 - 2.13.1 Rxi Pharmaceuticals Details
 - 2.13.2 Rxi Pharmaceuticals Major Business
 - 2.13.3 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Product and Solutions
 - 2.13.4 Rxi Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.13.5 Rxi Pharmaceuticals Recent Developments and Future Plans
- 2.14 Silenseed
 - 2.14.1 Silenseed Details
 - 2.14.2 Silenseed Major Business
 - 2.14.3 Silenseed Antisense & RNAi Therapeutics Product and Solutions
 - 2.14.4 Silenseed Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.14.5 Silenseed Recent Developments and Future Plans
- 2.15 Dicerna Pharmaceuticals
 - 2.15.1 Dicerna Pharmaceuticals Details
 - 2.15.2 Dicerna Pharmaceuticals Major Business
 - 2.15.3 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Product and Solutions
 - 2.15.4 Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
 - 2.15.5 Dicerna Pharmaceuticals Recent Developments and Future Plans
- 2.16 Sirnaomics Inc.
 - 2.16.1 Sirnaomics Inc. Details
 - 2.16.2 Sirnaomics Inc. Major Business
 - 2.16.3 Sirnaomics Inc. Antisense & RNAi Therapeutics Product and Solutions
 - 2.16.4 Sirnaomics Inc. Antisense & RNAi Therapeutics Revenue, Gross Margin and

Market Share (2018-2023)

2.16.5 Sirnaomics Inc. Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Antisense & RNAi Therapeutics Revenue and Share by Players (2018-2023)

3.2 Market Share Analysis (2022)

3.2.1 Market Share of Antisense & RNAi Therapeutics by Company Revenue

3.2.2 Top 3 Antisense & RNAi Therapeutics Players Market Share in 2022

3.2.3 Top 6 Antisense & RNAi Therapeutics Players Market Share in 2022

3.3 Antisense & RNAi Therapeutics Market: Overall Company Footprint Analysis

3.3.1 Antisense & RNAi Therapeutics Market: Region Footprint

3.3.2 Antisense & RNAi Therapeutics Market: Company Product Type Footprint

3.3.3 Antisense & RNAi Therapeutics Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Antisense & RNAi Therapeutics Consumption Value and Market Share by Type (2018-2023)

4.2 Global Antisense & RNAi Therapeutics Market Forecast by Type (2024-2029)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Antisense & RNAi Therapeutics Consumption Value Market Share by Application (2018-2023)

5.2 Global Antisense & RNAi Therapeutics Market Forecast by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Antisense & RNAi Therapeutics Consumption Value by Type (2018-2029)

6.2 North America Antisense & RNAi Therapeutics Consumption Value by Application (2018-2029)

6.3 North America Antisense & RNAi Therapeutics Market Size by Country

6.3.1 North America Antisense & RNAi Therapeutics Consumption Value by Country (2018-2029)

6.3.2 United States Antisense & RNAi Therapeutics Market Size and Forecast

(2018-2029)

6.3.3 Canada Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

6.3.4 Mexico Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

7 EUROPE

7.1 Europe Antisense & RNAi Therapeutics Consumption Value by Type (2018-2029)

7.2 Europe Antisense & RNAi Therapeutics Consumption Value by Application
(2018-2029)

7.3 Europe Antisense & RNAi Therapeutics Market Size by Country

7.3.1 Europe Antisense & RNAi Therapeutics Consumption Value by Country
(2018-2029)

7.3.2 Germany Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

7.3.3 France Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

7.3.4 United Kingdom Antisense & RNAi Therapeutics Market Size and Forecast
(2018-2029)

7.3.5 Russia Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

7.3.6 Italy Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

8 ASIA-PACIFIC

8.1 Asia-Pacific Antisense & RNAi Therapeutics Consumption Value by Type
(2018-2029)

8.2 Asia-Pacific Antisense & RNAi Therapeutics Consumption Value by Application
(2018-2029)

8.3 Asia-Pacific Antisense & RNAi Therapeutics Market Size by Region

8.3.1 Asia-Pacific Antisense & RNAi Therapeutics Consumption Value by Region
(2018-2029)

8.3.2 China Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

8.3.3 Japan Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

8.3.4 South Korea Antisense & RNAi Therapeutics Market Size and Forecast
(2018-2029)

8.3.5 India Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

8.3.6 Southeast Asia Antisense & RNAi Therapeutics Market Size and Forecast
(2018-2029)

8.3.7 Australia Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

9 SOUTH AMERICA

9.1 South America Antisense & RNAi Therapeutics Consumption Value by Type (2018-2029)

9.2 South America Antisense & RNAi Therapeutics Consumption Value by Application (2018-2029)

9.3 South America Antisense & RNAi Therapeutics Market Size by Country

9.3.1 South America Antisense & RNAi Therapeutics Consumption Value by Country (2018-2029)

9.3.2 Brazil Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

9.3.3 Argentina Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Antisense & RNAi Therapeutics Consumption Value by Type (2018-2029)

10.2 Middle East & Africa Antisense & RNAi Therapeutics Consumption Value by Application (2018-2029)

10.3 Middle East & Africa Antisense & RNAi Therapeutics Market Size by Country

10.3.1 Middle East & Africa Antisense & RNAi Therapeutics Consumption Value by Country (2018-2029)

10.3.2 Turkey Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

10.3.3 Saudi Arabia Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

10.3.4 UAE Antisense & RNAi Therapeutics Market Size and Forecast (2018-2029)

11 MARKET DYNAMICS

11.1 Antisense & RNAi Therapeutics Market Drivers

11.2 Antisense & RNAi Therapeutics Market Restraints

11.3 Antisense & RNAi Therapeutics Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

11.5 Influence of COVID-19 and Russia-Ukraine War

11.5.1 Influence of COVID-19

11.5.2 Influence of Russia-Ukraine War

12 INDUSTRY CHAIN ANALYSIS

- 12.1 Antisense & RNAi Therapeutics Industry Chain
- 12.2 Antisense & RNAi Therapeutics Upstream Analysis
- 12.3 Antisense & RNAi Therapeutics Midstream Analysis
- 12.4 Antisense & RNAi Therapeutics Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

- 14.1 Methodology
- 14.2 Research Process and Data Source
- 14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Antisense & RNAi Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global Antisense & RNAi Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. Global Antisense & RNAi Therapeutics Consumption Value by Region (2018-2023) & (USD Million)

Table 4. Global Antisense & RNAi Therapeutics Consumption Value by Region (2024-2029) & (USD Million)

Table 5. Glaxo Smith Kline Company Information, Head Office, and Major Competitors

Table 6. Glaxo Smith Kline Major Business

Table 7. Glaxo Smith Kline Antisense & RNAi Therapeutics Product and Solutions

Table 8. Glaxo Smith Kline Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 9. Glaxo Smith Kline Recent Developments and Future Plans

Table 10. Sanofi Aventis / Genzyme Company Information, Head Office, and Major Competitors

Table 11. Sanofi Aventis / Genzyme Major Business

Table 12. Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Product and Solutions

Table 13. Sanofi Aventis / Genzyme Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 14. Sanofi Aventis / Genzyme Recent Developments and Future Plans

Table 15. Isis Pharmaceuticals/ Ionis Pharmaceuticals Company Information, Head Office, and Major Competitors

Table 16. Isis Pharmaceuticals/ Ionis Pharmaceuticals Major Business

Table 17. Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Product and Solutions

Table 18. Isis Pharmaceuticals/ Ionis Pharmaceuticals Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 19. Isis Pharmaceuticals/ Ionis Pharmaceuticals Recent Developments and Future Plans

Table 20. Arbutus Biopharma Ltd. Company Information, Head Office, and Major Competitors

Table 21. Arbutus Biopharma Ltd. Major Business

Table 22. Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Product and

Solutions

Table 23. Arbutus Biopharma Ltd. Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 24. Arbutus Biopharma Ltd. Recent Developments and Future Plans

Table 25. Silence Therapeutics Company Information, Head Office, and Major Competitors

Table 26. Silence Therapeutics Major Business

Table 27. Silence Therapeutics Antisense & RNAi Therapeutics Product and Solutions

Table 28. Silence Therapeutics Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 29. Silence Therapeutics Recent Developments and Future Plans

Table 30. Bio-Path Holdings Inc. Company Information, Head Office, and Major Competitors

Table 31. Bio-Path Holdings Inc. Major Business

Table 32. Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Product and Solutions

Table 33. Bio-Path Holdings Inc. Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 34. Bio-Path Holdings Inc. Recent Developments and Future Plans

Table 35. Calando Pharmaceuticals Company Information, Head Office, and Major Competitors

Table 36. Calando Pharmaceuticals Major Business

Table 37. Calando Pharmaceuticals Antisense & RNAi Therapeutics Product and Solutions

Table 38. Calando Pharmaceuticals Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 39. Calando Pharmaceuticals Recent Developments and Future Plans

Table 40. ICo Therapeutics Company Information, Head Office, and Major Competitors

Table 41. ICo Therapeutics Major Business

Table 42. ICo Therapeutics Antisense & RNAi Therapeutics Product and Solutions

Table 43. ICo Therapeutics Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 44. ICo Therapeutics Recent Developments and Future Plans

Table 45. Quark Pharmaceuticals Company Information, Head Office, and Major Competitors

Table 46. Quark Pharmaceuticals Major Business

Table 47. Quark Pharmaceuticals Antisense & RNAi Therapeutics Product and Solutions

Table 48. Quark Pharmaceuticals Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 49. Quark Pharmaceuticals Recent Developments and Future Plans

Table 50. Rexhan Pharmaceuticals Company Information, Head Office, and Major Competitors

Table 51. Rexhan Pharmaceuticals Major Business

Table 52. Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Product and Solutions

Table 53. Rexhan Pharmaceuticals Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 54. Rexhan Pharmaceuticals Recent Developments and Future Plans

Table 55. Biomarin/Prosensa Company Information, Head Office, and Major Competitors

Table 56. Biomarin/Prosensa Major Business

Table 57. Biomarin/Prosensa Antisense & RNAi Therapeutics Product and Solutions

Table 58. Biomarin/Prosensa Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 59. Biomarin/Prosensa Recent Developments and Future Plans

Table 60. Regulus Therapeutics Company Information, Head Office, and Major Competitors

Table 61. Regulus Therapeutics Major Business

Table 62. Regulus Therapeutics Antisense & RNAi Therapeutics Product and Solutions

Table 63. Regulus Therapeutics Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 64. Regulus Therapeutics Recent Developments and Future Plans

Table 65. Rxi Pharmaceuticals Company Information, Head Office, and Major Competitors

Table 66. Rxi Pharmaceuticals Major Business

Table 67. Rxi Pharmaceuticals Antisense & RNAi Therapeutics Product and Solutions

Table 68. Rxi Pharmaceuticals Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 69. Rxi Pharmaceuticals Recent Developments and Future Plans

Table 70. Silenseed Company Information, Head Office, and Major Competitors

Table 71. Silenseed Major Business

Table 72. Silenseed Antisense & RNAi Therapeutics Product and Solutions

Table 73. Silenseed Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 74. Silenseed Recent Developments and Future Plans

Table 75. Dicerna Pharmaceuticals Company Information, Head Office, and Major Competitors

Table 76. Dicerna Pharmaceuticals Major Business

- Table 77. Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Product and Solutions
- Table 78. Dicerna Pharmaceuticals Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 79. Dicerna Pharmaceuticals Recent Developments and Future Plans
- Table 80. Sirnaomics Inc. Company Information, Head Office, and Major Competitors
- Table 81. Sirnaomics Inc. Major Business
- Table 82. Sirnaomics Inc. Antisense & RNAi Therapeutics Product and Solutions
- Table 83. Sirnaomics Inc. Antisense & RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 84. Sirnaomics Inc. Recent Developments and Future Plans
- Table 85. Global Antisense & RNAi Therapeutics Revenue (USD Million) by Players (2018-2023)
- Table 86. Global Antisense & RNAi Therapeutics Revenue Share by Players (2018-2023)
- Table 87. Breakdown of Antisense & RNAi Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
- Table 88. Market Position of Players in Antisense & RNAi Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
- Table 89. Head Office of Key Antisense & RNAi Therapeutics Players
- Table 90. Antisense & RNAi Therapeutics Market: Company Product Type Footprint
- Table 91. Antisense & RNAi Therapeutics Market: Company Product Application Footprint
- Table 92. Antisense & RNAi Therapeutics New Market Entrants and Barriers to Market Entry
- Table 93. Antisense & RNAi Therapeutics Mergers, Acquisition, Agreements, and Collaborations
- Table 94. Global Antisense & RNAi Therapeutics Consumption Value (USD Million) by Type (2018-2023)
- Table 95. Global Antisense & RNAi Therapeutics Consumption Value Share by Type (2018-2023)
- Table 96. Global Antisense & RNAi Therapeutics Consumption Value Forecast by Type (2024-2029)
- Table 97. Global Antisense & RNAi Therapeutics Consumption Value by Application (2018-2023)
- Table 98. Global Antisense & RNAi Therapeutics Consumption Value Forecast by Application (2024-2029)
- Table 99. North America Antisense & RNAi Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 100. North America Antisense & RNAi Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 101. North America Antisense & RNAi Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 102. North America Antisense & RNAi Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 103. North America Antisense & RNAi Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 104. North America Antisense & RNAi Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 105. Europe Antisense & RNAi Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 106. Europe Antisense & RNAi Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 107. Europe Antisense & RNAi Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 108. Europe Antisense & RNAi Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 109. Europe Antisense & RNAi Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 110. Europe Antisense & RNAi Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 111. Asia-Pacific Antisense & RNAi Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 112. Asia-Pacific Antisense & RNAi Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 113. Asia-Pacific Antisense & RNAi Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 114. Asia-Pacific Antisense & RNAi Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 115. Asia-Pacific Antisense & RNAi Therapeutics Consumption Value by Region (2018-2023) & (USD Million)

Table 116. Asia-Pacific Antisense & RNAi Therapeutics Consumption Value by Region (2024-2029) & (USD Million)

Table 117. South America Antisense & RNAi Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 118. South America Antisense & RNAi Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 119. South America Antisense & RNAi Therapeutics Consumption Value by

Application (2018-2023) & (USD Million)

Table 120. South America Antisense & RNAi Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 121. South America Antisense & RNAi Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 122. South America Antisense & RNAi Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 123. Middle East & Africa Antisense & RNAi Therapeutics Consumption Value by Type (2018-2023) & (USD Million)

Table 124. Middle East & Africa Antisense & RNAi Therapeutics Consumption Value by Type (2024-2029) & (USD Million)

Table 125. Middle East & Africa Antisense & RNAi Therapeutics Consumption Value by Application (2018-2023) & (USD Million)

Table 126. Middle East & Africa Antisense & RNAi Therapeutics Consumption Value by Application (2024-2029) & (USD Million)

Table 127. Middle East & Africa Antisense & RNAi Therapeutics Consumption Value by Country (2018-2023) & (USD Million)

Table 128. Middle East & Africa Antisense & RNAi Therapeutics Consumption Value by Country (2024-2029) & (USD Million)

Table 129. Antisense & RNAi Therapeutics Raw Material

Table 130. Key Suppliers of Antisense & RNAi Therapeutics Raw Materials

List Of Figures

LIST OF FIGURES

Figure 1. Antisense & RNAi Therapeutics Picture

Figure 2. Global Antisense & RNAi Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 3. Global Antisense & RNAi Therapeutics Consumption Value Market Share by Type in 2022

Figure 4. RNA Interference

Figure 5. SiRNA

Figure 6. MiRNA

Figure 7. Antisense RNA

Figure 8. Global Antisense & RNAi Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 9. Antisense & RNAi Therapeutics Consumption Value Market Share by Application in 2022

Figure 10. Oncology Picture

Figure 11. Cardiovascular Picture

Figure 12. Renal Picture

Figure 13. Neurodegenerative Picture

Figure 14. Respiratory Picture

Figure 15. Genetic Picture

Figure 16. Infectious Diseases Picture

Figure 17. Global Antisense & RNAi Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029

Figure 18. Global Antisense & RNAi Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)

Figure 19. Global Market Antisense & RNAi Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)

Figure 20. Global Antisense & RNAi Therapeutics Consumption Value Market Share by Region (2018-2029)

Figure 21. Global Antisense & RNAi Therapeutics Consumption Value Market Share by Region in 2022

Figure 22. North America Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 23. Europe Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 24. Asia-Pacific Antisense & RNAi Therapeutics Consumption Value

(2018-2029) & (USD Million)

Figure 25. South America Antisense & RNAi Therapeutics Consumption Value

(2018-2029) & (USD Million)

Figure 26. Middle East and Africa Antisense & RNAi Therapeutics Consumption Value

(2018-2029) & (USD Million)

Figure 27. Global Antisense & RNAi Therapeutics Revenue Share by Players in 2022

Figure 28. Antisense & RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022

Figure 29. Global Top 3 Players Antisense & RNAi Therapeutics Market Share in 2022

Figure 30. Global Top 6 Players Antisense & RNAi Therapeutics Market Share in 2022

Figure 31. Global Antisense & RNAi Therapeutics Consumption Value Share by Type (2018-2023)

Figure 32. Global Antisense & RNAi Therapeutics Market Share Forecast by Type (2024-2029)

Figure 33. Global Antisense & RNAi Therapeutics Consumption Value Share by Application (2018-2023)

Figure 34. Global Antisense & RNAi Therapeutics Market Share Forecast by Application (2024-2029)

Figure 35. North America Antisense & RNAi Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 36. North America Antisense & RNAi Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 37. North America Antisense & RNAi Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 38. United States Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 39. Canada Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 40. Mexico Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 41. Europe Antisense & RNAi Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 42. Europe Antisense & RNAi Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 43. Europe Antisense & RNAi Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 44. Germany Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 45. France Antisense & RNAi Therapeutics Consumption Value (2018-2029) &

(USD Million)

Figure 46. United Kingdom Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 47. Russia Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 48. Italy Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 49. Asia-Pacific Antisense & RNAi Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 50. Asia-Pacific Antisense & RNAi Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 51. Asia-Pacific Antisense & RNAi Therapeutics Consumption Value Market Share by Region (2018-2029)

Figure 52. China Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 53. Japan Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 54. South Korea Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 55. India Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 56. Southeast Asia Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 57. Australia Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 58. South America Antisense & RNAi Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 59. South America Antisense & RNAi Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 60. South America Antisense & RNAi Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 61. Brazil Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 62. Argentina Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 63. Middle East and Africa Antisense & RNAi Therapeutics Consumption Value Market Share by Type (2018-2029)

Figure 64. Middle East and Africa Antisense & RNAi Therapeutics Consumption Value Market Share by Application (2018-2029)

Figure 65. Middle East and Africa Antisense & RNAi Therapeutics Consumption Value Market Share by Country (2018-2029)

Figure 66. Turkey Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 67. Saudi Arabia Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 68. UAE Antisense & RNAi Therapeutics Consumption Value (2018-2029) & (USD Million)

Figure 69. Antisense & RNAi Therapeutics Market Drivers

Figure 70. Antisense & RNAi Therapeutics Market Restraints

Figure 71. Antisense & RNAi Therapeutics Market Trends

Figure 72. Porters Five Forces Analysis

Figure 73. Manufacturing Cost Structure Analysis of Antisense & RNAi Therapeutics in 2022

Figure 74. Manufacturing Process Analysis of Antisense & RNAi Therapeutics

Figure 75. Antisense & RNAi Therapeutics Industrial Chain

Figure 76. Methodology

Figure 77. Research Process and Data Source

I would like to order

Product name: Global Antisense & RNAi Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/G667190A45D6EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G667190A45D6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

